Biomarker Panel Predicts COPD Lung Function Decline
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the ability to predict lung function decline in individuals with chronic obstructive pulmonary disease (COPD), failing to discriminate between those with stable and declining lung function, which hinders targeted treatment and management.
Innovation Solution
The detection of specific biomarkers such as SIGLEC7, IGFBP1, GPC2, LYVE1, PSPN, CCDC80, IGFBP-7, PIGR, ANGPT2, GSK3β, LTA LTB, FGF19, CCL5, THPO, MST1R, CHST15, COL18A1, FST, HS6ST1, LGALS3, IL10, and LGMN in a sample from a subject to form a biomarker panel, allowing for the prediction of lung function decline or COPD progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional spirometry methods are used to diagnose COPD, then lung function can be measured, but the ability to predict future lung function decline is lost
Solution Approach 1:
The patent applies preliminary action by detecting biomarkers in advance before lung function decline occurs. The biomarker panel is measured at baseline to predict future prognosis, allowing clinical intervention before severe deterioration happens. This transforms reactive monitoring into proactive prediction.
Solution Approach 2:
The patent uses biomarkers as intermediary molecules that mediate between lung pathology and measurable signals. These biomarkers serve as proxies for underlying disease processes, translating complex physiological changes into detectable molecular signals that can be measured in body fluids.
2Reliability
If no biomarker panel is used, then the diagnostic approach remains simple, but discrimination between stable and declining lung function is impossible
Solution Approach 1:
The patent segments the complex diagnostic task into multiple independent biomarker measurements. Instead of relying on a single complex test, the system divides prognosis prediction into measuring individual biomarkers (SIGLEC7, IGFBP1, GPC2, etc.) and interpreting their combined pattern, making the complex prediction problem manageable through modular components.
Solution Approach 2:
The patent creates a composite diagnostic approach by combining multiple biomarkers into a panel. The prognostic value arises from the composite pattern of multiple markers rather than any single marker alone, similar to how composite materials achieve superior properties through combination of constituent materials.
Data Source
AI summary
Methods, compositions, and kits for predicting whether a subject with chronic obstructive pulmonary disease (COPD) or at risk of developing COPD is likely to have progressive COPD are provided. Methods, compositions, and kits for predicting whether lung function is likely to decline in a subject with COPD or at risk for developing COPD are also provided.